Mark Lebwohl

55.5k total citations · 18 hit papers
847 papers, 36.1k citations indexed

About

Mark Lebwohl is a scholar working on Immunology, Dermatology and Epidemiology. According to data from OpenAlex, Mark Lebwohl has authored 847 papers receiving a total of 36.1k indexed citations (citations by other indexed papers that have themselves been cited), including 513 papers in Immunology, 407 papers in Dermatology and 136 papers in Epidemiology. Recurrent topics in Mark Lebwohl's work include Psoriasis: Treatment and Pathogenesis (480 papers), Dermatology and Skin Diseases (291 papers) and Autoimmune Bullous Skin Diseases (108 papers). Mark Lebwohl is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (480 papers), Dermatology and Skin Diseases (291 papers) and Autoimmune Bullous Skin Diseases (108 papers). Mark Lebwohl collaborates with scholars based in United States, Canada and Germany. Mark Lebwohl's co-authors include Alan Menter, John Koo, Alice B. Gottlieb, Richard G. Langley, Abby S. Van Voorhees, Neil J. Korman, Kristian Reich, Kim Papp, Kenneth B. Gordon and Steven R. Feldman and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Mark Lebwohl

789 papers receiving 34.8k citations

Hit Papers

Secukinumab in Plaque Psoriasis — Results... 2001 2026 2009 2017 2014 2008 2008 2001 2016 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
    2014 1.5k citations Richard G. Langley, Boni E. Elewski et al. profile →
  2. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
    2008 1.1k citations Kim Papp, Richard G. Langley et al. profile →
  3. Guidelines of care for the management of psoriasis and psoriatic arthritis
    2008 964 citations Alan Menter, Alice B. Gottlieb et al. Journal of the American Academy of Dermatology profile →
  4. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.
    2001 790 citations Mark Lebwohl, Alan Menter et al. profile →
  5. Psoriasis
    2016 687 citations Mark Lebwohl, Nehal N. Mehta et al. profile →
  6. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
    2015 658 citations C.E.M. Griffiths, Mark Lebwohl et al. profile →
  7. Guidelines of care for the management of psoriasis and psoriatic arthritis
    2008 612 citations Alice B. Gottlieb, Kenneth B. Gordon et al. Journal of the American Academy of Dermatology profile →
  8. A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
    2007 588 citations Richard G. Langley, Mark Lebwohl et al. profile →
  9. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
    2018 452 citations Kenneth B. Gordon, Bruce Strober et al. profile →
  10. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults
    2016 415 citations Mark Lebwohl, Linda Stein Gold et al. Journal of the American Academy of Dermatology profile →
  11. Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
    2014 411 citations Mark Lebwohl, H. Bachelez et al. Journal of the American Academy of Dermatology profile →
  12. Ingenol Mebutate Gel for Actinic Keratosis
    2012 337 citations Mark Lebwohl, Brian Berman et al. profile →
  13. Psoriasis: Which therapy for which patient
    2018 274 citations Mark Lebwohl et al. Journal of the American Academy of Dermatology profile →
  14. Bimekizumab versus Secukinumab in Plaque Psoriasis
    2021 230 citations Richard B. Warren, Mark Lebwohl et al. profile →
  15. Trial of Spesolimab for Generalized Pustular Psoriasis
    2021 194 citations Akimichi Morita, Milan J. Anadkat et al. profile →
  16. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
    2021 169 citations Kim Papp, Andrew Blauvelt et al. profile →
  17. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo
    2022 133 citations David Rosmarin, Thierry Passeron et al. profile →
  18. Remibrutinib in Chronic Spontaneous Urticaria
    2025 25 citations Michihiro Hide, Mark Lebwohl et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Lebwohl United States 94 23.0k 18.1k 5.7k 5.1k 4.1k 847 36.1k
Kim Papp Canada 85 24.4k 1.1× 16.3k 0.9× 7.2k 1.3× 4.3k 0.8× 2.2k 0.5× 542 32.6k
Kristian Reich Germany 80 20.2k 0.9× 14.0k 0.8× 5.0k 0.9× 3.7k 0.7× 2.2k 0.5× 497 26.2k
Alan Menter United States 80 19.1k 0.8× 12.2k 0.7× 4.7k 0.8× 3.5k 0.7× 1.9k 0.5× 387 25.4k
Alice B. Gottlieb United States 90 23.1k 1.0× 12.3k 0.7× 8.9k 1.6× 3.5k 0.7× 2.3k 0.6× 602 31.4k
James G. Krueger United States 126 30.7k 1.3× 25.1k 1.4× 5.7k 1.0× 3.7k 0.7× 2.9k 0.7× 495 49.7k
Joel M. Gelfand United States 77 14.3k 0.6× 9.1k 0.5× 5.1k 0.9× 2.4k 0.5× 2.1k 0.5× 283 21.7k
Giampiero Girolomoni Italy 81 12.5k 0.5× 9.9k 0.5× 3.7k 0.6× 2.0k 0.4× 2.4k 0.6× 558 23.7k
Juliet N. Barker United States 85 17.3k 0.8× 9.0k 0.5× 2.8k 0.5× 2.6k 0.5× 2.9k 0.7× 559 31.3k
L. Puig Spain 57 11.2k 0.5× 7.7k 0.4× 3.8k 0.7× 2.2k 0.4× 2.5k 0.6× 626 18.2k
Thomas Ruzicka Germany 81 6.2k 0.3× 11.9k 0.7× 3.2k 0.6× 3.2k 0.6× 3.8k 0.9× 672 26.2k

Countries citing papers authored by Mark Lebwohl

Since Specialization
Citations

This map shows the geographic impact of Mark Lebwohl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lebwohl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lebwohl more than expected).

Fields of papers citing papers by Mark Lebwohl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Lebwohl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lebwohl. The network helps show where Mark Lebwohl may publish in the future.

Co-authorship network of co-authors of Mark Lebwohl

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Lebwohl. A scholar is included among the top collaborators of Mark Lebwohl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Lebwohl. Mark Lebwohl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lebwohl, Mark, Atul Deodhar, Sergio Schwartzman, et al.. (2025). Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events. Dermatology and Therapy. 15(1). 161–188. 2 indexed citations
2.
Langley, Richard G., Mark Lebwohl, Bruce Strober, et al.. (2025). Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. Journal of the American Academy of Dermatology. 93(3). 644–653. 1 indexed citations
3.
Lebwohl, Mark, Edward Lain, Amy McMichael, Maryanne M. Senna, & Natasha Atanaskova Mesinkovska. (2025). Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors. SHILAP Revista de lepidopterología. 7. 1–8.
4.
Harris, John E., Amit G. Pandya, Mark Lebwohl, et al.. (2024). Safety and Efficacy of Ruxolitinib Cream for the Treatment of Vitiligo: A Randomised Controlled Trial Secondary Analysis at 3 Years. SHILAP Revista de lepidopterología. 4(6). e404–e404. 7 indexed citations
5.
Gold, Linda Stein, Andrew Blauvelt, Leon Kircik, et al.. (2024). Efficacy of Deucravacitinib in Moderate to Severe Scalp Psoriasis: Analysis of Complete Clearance of Scalp Disease and Symptoms. SKIN The Journal of Cutaneous Medicine. 8(6). s430–s430. 1 indexed citations
6.
Kim, Brian, Sonja Ständer, Kenji Kabashima, et al.. (2024). Notalgia Paresthetica Dermatologist Report of Symptom Burden and Treatment: Results from a Physician Survey. Acta Dermato Venereologica. 104. adv39941–adv39941. 2 indexed citations
7.
Guénin, Samuel, Saakshi Khattri, & Mark Lebwohl. (2023). 11 Spesolimab use in treatment of severe pyoderma Gangrenosum. Journal of Investigative Dermatology. 143(11). S334–S334. 1 indexed citations
8.
Lebwohl, Mark, Richard B. Warren, Howard Sofen, et al.. (2023). Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program. SKIN The Journal of Cutaneous Medicine. 7(2). s118–s118. 3 indexed citations
9.
Gold, Linda Stein, C.E.M. Griffiths, Anna M. Tallman, Philip Marshall Brown, & Mark Lebwohl. (2023). Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials. SKIN The Journal of Cutaneous Medicine. 7(2). s123–s123. 1 indexed citations
10.
Lebwohl, Mark, Bruce Strober, Misti Linaberry, et al.. (2023). Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials. SKIN The Journal of Cutaneous Medicine. 7(2). s115–s115. 1 indexed citations
11.
Pellacani, Giovanni, Tobias Schlesinger, Neal Bhatia, et al.. (2023). Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: Data from two phase‐III trials and the real‐life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022. Journal of the European Academy of Dermatology and Venereology. 38(S1). 3–15. 5 indexed citations
12.
Saini, Sarbjit S., Ana M. Giménez‐Arnau, Michihiro Hide, et al.. (2023). FAST SYMPTOM IMPROVEMENT AND FAVORABLE SAFETY PROFILE WITH REMIBRUTINIB IN CHRONIC SPONTANEOUS URTICARIA: REMIX-1/-2 STUDIES. Annals of Allergy Asthma & Immunology. 131(5). S230–S230. 5 indexed citations
13.
Lebwohl, Mark, et al.. (2023). Oral Jak Inhibitor Upadacitinib Use in Treatment of Pemphigus Foliaceus. SKIN The Journal of Cutaneous Medicine. 7(4). 881–885. 2 indexed citations
14.
Guttman‐Yassky, Emma, Paola Facheris, Joel Corrêa da Rosa, et al.. (2023). Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis. Journal of Allergy and Clinical Immunology. 152(4). 916–926. 16 indexed citations
15.
Lebwohl, Mark, Lars Iversen, Liv Eidsmo, et al.. (2023). Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studies. Clinical and Experimental Dermatology. 49(8). 793–800. 10 indexed citations
16.
Schlesinger, Todd, Leon Kircik, J.Q. Del Rosso, et al.. (2023). Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study). SKIN The Journal of Cutaneous Medicine. 7(3). 771–787. 4 indexed citations
17.
Elewski, Boni E., Mark Lebwohl, Milan J. Anadkat, et al.. (2023). Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study. Journal of the American Academy of Dermatology. 89(1). 36–44. 21 indexed citations
18.
Gold, Linda Stein, et al.. (2023). 41626 Tapinarof Cream 1% Once Daily for Plaque Psoriasis in Two Pivotal Phase 3 Trials: Minimal Systemic Exposure is Consistent With Adverse Event Profile. Journal of the American Academy of Dermatology. 89(3). AB229–AB229. 2 indexed citations
19.
Hadi, Suhail, et al.. (2010). The Use of the 308-nm Excimer Laser for the Treatment of Psoriasis. Photomedicine and Laser Surgery. 28(5). 693–695. 9 indexed citations
20.
Hadi, Suhail, et al.. (2006). Treatment of Vitiligo Using the 308-nm Excimer Laser. Photomedicine and Laser Surgery. 24(3). 354–357. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kim Papp Breakdown of academic impact, for papers by Kristian Reich Breakdown of academic impact, for papers by Alan Menter Breakdown of academic impact, for papers by Alice B. Gottlieb Breakdown of academic impact, for papers by James G. Krueger Breakdown of academic impact, for papers by Joel M. Gelfand Breakdown of academic impact, for papers by Giampiero Girolomoni Breakdown of academic impact, for papers by Juliet N. Barker Breakdown of academic impact, for papers by L. Puig Breakdown of academic impact, for papers by Thomas Ruzicka
Rankless by CCL
2026